Voxvoganan (LTX-109) tridrochloride, a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan tridrochloride can be used for the research of fungal infections and nasal decolonisation of MRSA[1][2].
Voxvoganan tridrochloride (LTX-109) is an investigational antimicrobial agent with a membrane-lysing mechanism of action, based on the biological principle of innate immune effectors, lytic peptides. Voxvoganan tridrochloride has a rapid bactericidal lytic activity. Voxvoganan tridrochloride demonstrates in vitro bactericidal activity against a number of S. aureus isolates resistant to several classes of antimicrobial agents evaluated in this study[2].
Voxvoganan tridrochloride (LTX-109) is a broad-spectrum, fast-acting bactericidal antimicrobial agent that binds to negatively charged membrane components on the bacterial cell wall, which leads to membrane disruption and cell lysis. Voxvoganan tridrochloride is a first-in-class chemically synthesized, small peptide drug that is stable against protease degradation. Topical application of Voxvoganan tridrochloride has a good safety profile and a low bioavailability. Voxvoganan tridrochloride demonstrates good activity against Staplococcus aureus strains that are susceptible and resistant to mupirocin[3].
[1]. Johan Isaksson, et al. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.
[2]. Louis D Saravolatz, et al. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staplococcus aureus. Antimicrob Agents Chemother. 2012 Aug;56(8):4478-82.
[3]. L D Saravolatz, et al. Postantibiotic effect and postantibiotic sub-MIC effect of LTX-109 and mupirocin on Staplococcus aureus blood isolates. Lett Appl Microbiol. 2017 Nov;65(5):410-413.